Molecular actions of vitamin D contributing to cancer prevention

Molecular Aspects of Medicine

Volumn 29, Issue 6, 2008, Pages 388-396

  Fleet, James C ^a  

^a PURDUE UNIVERSITY   (United States)

Author keywords

1,25 Dihydroxyvitamin D; 25 Hydroxyvitamin D; Apoptosis; Proliferation; Transcription; Vitamin D receptor

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; SEOCALCITOL; VITAMIN D;

BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CANCER PREVENTION; CANCER RISK; CELL PROLIFERATION; COLON CANCER; GENETIC TRANSCRIPTION; HUMAN; IMMUNE SYSTEM; IMMUNOMODULATION; MELANOMA; MICROARRAY ANALYSIS; NONHUMAN; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; VITAMIN D METABOLISM;

ANIMALS; CELL PROLIFERATION; HUMANS; NEOPLASM STAGING; NEOPLASMS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION; VITAMIN D;

EID: 56049098150     PISSN: 00982997     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mam.2008.07.003     Document Type: Review

References (76)

1. Adams J.S., Liu P.T., Chun R., Modlin R.L., and Hewison M. Vitamin D in defense of the human immune response. Ann. NY Acad. Sci. 1117 (2007) 94-105
2. Aguilera O., Pena C., Garcia J.M., Larriba M.J., Ordonez-Moran P., Navarro D., Barbachano A., Lopez dS I., Ballestar E., Fraga M.F., Esteller M., Gamallo C., Bonilla F., Gonzalez-Sancho J.M., and Munoz A. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28 (2007) 1877-1884
3. Akutsu N., Lin R., Bastien Y., Bestawros A., Enepekides D.J., Black M.J., and White J.H. Regulation of gene expression by 1alpha, 25-dihydroxyvitamin D3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells. Mol. Endocrinol. 15 (2001) 1127-1139
4. Albertson D.G., Ylstra B., Segraves R., Collins C., Dairkee S.H., Kowbel D., Kuo W.L., Gray J.W., and Pinkel D. Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene. Nat. Genet. 25 (2000) 144-146
5. Anderson M.G., Nakane M., Ruan X., Kroeger P.E., and Wu-Wong J.R. Expression of VDR and CYP24A1 mRNA in human tumors. Cancer Chemother. Pharmacol. 57 (2006) 234-240
6. Apperly F.L. The relation of solar radiation to cancer mortality in North American. Cancer Res. 1 (1941) 191-195
7. Barsony J., Pike J.W., DeLuca H.F., and Marx S.J. Immunocytology with microwave-fixed fibroblasts shows 1 alpha, 25-dihydroxyvitamin D3-dependent rapid and estrogen-dependent slow reorganization of vitamin D receptors. J. Cell Biol. 111 (1990) 2385-2395
8. Barsony J., Renyi I., and McKoy W. Subcellular distribution of normal and mutant vitamin D receptors in living cells. J. Biol. Chem. 272 (1997) 5774-5782
9. Belandia B., Orford R.L., Hurst H.C., and Parker M.G. Targeting of SWI/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO. J. 21 (2002) 4094-4103
10. Cantorna M.T., and Mahon B.D. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp. Biol. Med. (Maywood) 229 (2004) 1136-1142
11. Cantorna M.T., Zhu Y., Froicu M., and Wittke A. Vitamin D status, 1, 25-dihydroxyvitamin D3, and the immune system. Am. J. Clin. Nutr. 80 (2004) 1717S-1720S
12. Chen H., Lin R.J., Xie W., Wilpitz D., and Evans R.M. Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase. Cell 98 (1999) 675-686
13. Chen T.C., Wang L., Whitlatch L.W., Flanagan J.N., and Holick M.F. Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. J. Cell Biochem. 88 (2003) 315-322
14. Colston K., Colston M.J., and Feldman D. 1, 25-dihydroxyvitamin D3 and malignant melanoma: the presence of receptors and inhibition of cell growth in culture. Endocrinology 108 (1981) 1083-1086
15. Colston K.W., Perks C.M., Xie S.P., and Holly J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J. Mol. Endocrinol. 20 (1998) 157-162
16. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 (2002) 860-867
17. Diaz G.D., Paraskeva C., Thomas M.G., Binderup L., and Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: possible implications for prevention and therapy. Cancer Res. 60 (2000) 2304-2312
18. Eelen G., Verlinden L., Van Camp M., Van Hummelen P., Marchal K., De Moor B., Mathieu C., Carmeliet G., Bouillon R., and Verstuyf A. The effects of 1alpha, 25-dihydroxyvitamin D3 on the expression of DNA replication genes. J. Bone Miner. Res. 19 (2004) 133-146
19. Escaleira M.T., and Brentani M.M. Vitamin D3 receptor (VDR) expression in HC-11 mammary cells: regulation by growth-modulatory agents, differentiation, and Ha-ras transformation. Breast Cancer Res. Treat. 54 (1999) 123-133
20. Fearon E.R., and Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 61 (1990) 759-767
21. Fleet J.C. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean?. J. Nutr. 134 (2004) 3215-3218
22. Fleet J.C. Molecular regulation of calcium metabolism. In: Weaver C.M., and Heaney R.P. (Eds). Calcium in Human Health (2006), Humana Press, Totowa, NJ 163-190
23. Freedman L.P. Increasing the complexity of coactivation in nuclear receptor signaling. Cell 97 (1999) 5-8
24. Friedrich M., Diesing D., Cordes T., Fischer D., Becker S., Chen T.C., Flanagan J.N., Tangpricha V., Gherson I., Holick M.F., and Reichrath J. Analysis of 25-hydroxyvitamin D3-1alpha-hydroxylase in normal and malignant breast tissue. Anticancer Res. 26 (2006) 2615-2620
25. Garland C.F., and Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. Int. J. Epidemiol. 9 (1980) 227-231
26. Gervaz P., Bucher P., and Morel P. Two colons-two cancers: paradigm shift and clinical implications. J. Surg. Oncol. 88 (2004) 261-266
27. Giovannucci E. Commentary: vitamin D and colorectal cancer-twenty-five years later. Int. J. Epidemiol. 35 (2006) 222-224
28. Griffin M.D., Dong X., and Kumar R. Vitamin D receptor-mediated suppression of RelB in antigen presenting cells: a paradigm for ligand-augmented negative transcriptional regulation. Arch. Biochem. Biophys. 460 (2007) 218-226
29. Gross M., Kost S.B., Ennis B., Stumpf W., and Kumar R. Effect of 1, 25-dihydroxyvitamin D3 on mouse mammary tumor (GR) cells: evidence for receptors, cellular uptake, inhibition of growth and alteration in morphology at physiologic concentrations of hormone. J. Bone Miner. Res. 1 (1986) 457-467
30. Hager G., Formanek M., Gedlicka C., Thurnher D., Knerer B., and Kornfehl J. 1, 25(OH)2 vitamin D3 induces elevated expression of the cell cycle-regulating genes P21 and P27 in squamous carcinoma cell lines of the head and neck. Acta Otolaryngol. 121 (2001) 103-109
31. Hager G., Kornfehl J., Knerer B., Weigel G., and Formanek M. Molecular analysis of p21 promoter activity isolated from squamous carcinoma cell lines of the head and neck under the influence of 1, 25(OH)2 vitamin D3 and its analogs. Acta Otolaryngol. 124 (2004) 90-96
32. Haussler M.R., Whitfield G.K., Haussler C.A., Hsieh J.C., Thompson P.D., Selznick S.H., Dominguez C.E., and Jurutka P.W. The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J. Bone Miner. Res. 13 (1998) 325-349
33. Haverkamp J., Charbonneau B., and Ratliff T.L. Prostate inflammation and its potential impact on prostate cancer: a current review. J. Cell Biochem. (2007)
34. Hedlund T.E., Moffatt K.A., and Miller G.J. Vitamin D receptor expression is required for growth modulation by 1 alpha, 25-dihydroxyvitamin D3 in the human prostatic carcinoma cell line ALVA-31. J. Steroid Biochem. Mol. Biol. 58 (1996) 277-288
35. Hedlund T.E., Moffatt K.A., and Miller G.J. Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence thqt the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway. Endocrinology 137 (1996) 1554-1561
36. Hewison M., Zehnder D., Bland R., and Stewart P.M. 1alpha-Hydroxylase and the action of vitamin D. J. Mol. Endocrinol. 25 (2000) 141-148
37. Hill R., Song Y., Cardiff R.D., and Van Dyke T. Selective evolution of stromal mesenchyme with p53 loss in response to epithelial tumorigenesis. Cell 123 (2005) 1001-1011
38. Holt P.R., Arber N., Halmos B., Forde K., Kissileff H., McGlynn K.A., Moss S.F., Kurihara N., Fan K., Yang K., and Lipkin M. Colonic epithelial cell proliferation decreases with increasing levels of serum 25-hydroxy vitamin D. Cancer Epidemiol. Biomarkers Prev. 11 (2002) 113-119
39. Hsu J.Y., Feldman D., McNeal J.E., and Peehl D.M. Reduced 1alpha-hydroxylase activity in human prostate cancer cells correlates with decreased susceptibility to 25-hydroxyvitamin D3-induced growth inhibition. Cancer Res. 61 (2001) 2852-2856
40. Huhtakangas J.A., Olivera C.J., Bishop J.E., Zanello L.P., and Norman A.W. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1{alpha}, 25(OH)2-vitamin D3 in vivo and in vitro. Mol Endocrinol. 18 (2004) 2660-2671
41. Huynh H., Pollak M., and Zhang J.C. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1, 25(OH)2D3 and its analog EB1089. Int. J. Oncol. 13 (1998) 137-143
42. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., Fujii S., and Kiyosawa K. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. Br. J. Cancer 76 (1997) 884-889
43. Krishnan A.V., Shinghal R., Raghavachari N., Brooks J.D., Peehl D.M., and Feldman D. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays. Prostate 59 (2004) 243-251
44. Lin R., Nagai Y., Sladek R., Bastien Y., Ho J., Petrecca K., Sotiropoulou G., Diamandis E.P., Hudson T.J., and White J.H. Expression profiling in squamous carcinoma cells reveals pleiotropic effects of vitamin D(3) analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol. Endocrinol. 16 (2002) 1243-1256
45. Liu M., Lee M.H., Cohen M., Bommakanti M., and Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D leads to the induced differentiation of the myelomonocytic cell line U937. Genes Develop. 10 (1996) 142-153
46. Lointier P., Wargovich M.J., Saez S., Levin B., Wildrick D.M., and Boman B.M. The role of vitamin D3 in the proliferation of a human colon cancer cell line in vitro. Anticancer Res. 7 (1987) 817-821
47. Lou Y.R., Laaksi I., Syvala H., Blauer M., Tammela T.L., Ylikomi T., and Tuohimaa P. 25-Hydroxyvitamin D3 is an active hormone in human primary prostatic stromal cells. FASEB J. 18 (2004) 332-334
48. Macleod K. Tumor suppressor genes. Curr. Opin. Genet. Dev. 10 (2000) 81-93
49. Matusiak D., and Benya R.V. CYP27A1 and CYP24 expression as a function of malignant transformation in the colon. J. Histochem. Cytochem. 55 (2007) 1257-1264
50. Matusiak D., Murillo G., Carroll R.E., Mehta R.G., and Benya R.V. Expression of vitamin D receptor and 25-hydroxyvitamin D3-1{alpha}-hydroxylase in normal and malignant human colon. Cancer Epidemiol. Biomarkers Prev. 14 (2005) 2370-2376
51. Moffatt K.A., Johannes W.U., Hedlund T.E., and Miller G.J. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Res. 61 (2001) 7122-7129
52. Monti S., Proietti-Pannunzi L., Sciarra A., Lolli F., Falasca P., Poggi M., Celi F.S., and Toscano V. The IGF axis in prostate cancer. Curr. Pharm. Des. 13 (2007) 719-727
53. Moreno J., Krishnan A.V., and Feldman D. Molecular mechanisms mediating the anti-proliferative effects of vitamin D in prostate cancer. J. Steroid Biochem. Mol. Biol. 97 (2005) 31-36
54. Narvaez C.J., and Welsh J. Differential effects of 1, 25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology 138 (1997) 4690-4698
55. Nickerson T., and Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J. Endocrinol. 160 (1999) 223-229
56. Palmer H.G., Gonzalez-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., Quintanilla M., Cano A., de Herreros A.G., Lafarga M., and Munoz A. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. J. Cell Biol. 154 (2001) 369-387
57. Pendas-Franco N., Garcia J.M., Pena C., Valle N., Palmer H.G., Heinaniemi M., Carlberg C., Jimenez B., Bonilla F., Munoz A., and Gonzalez-Sancho J.M. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D(3). Oncogene (2008)
58. Peng L.H., Malloy P.J., and Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol. Endocrinol. 18 (2004) 1109-1119
59. Pike J.W., Zella L.A., Meyer M.B., Fretz J.A., and Kim S. Molecular actions of 1,25-dihydroxyvitamin D3 on genes involved in calcium homeostasis. J. Bone Miner. Res. 22 Suppl 2 (2007) V16-V19
60. Prufer K., and Barsony J. Retinoid X receptor dominates the nuclear import and export of the unliganded vitamin D receptor. Mol. Endocrinol. 16 (2002) 1738-1751
61. Prufer K., Racz A., Lin G.C., and Barsony J. Dimerization with retinoid X receptors promotes nuclear localization and subnuclear targeting of vitamin D receptors. J. Biol. Chem. 275 (2000) 41114-41123
62. Rachez C., Lemon B.D., Suldan Z., Bromleigh V., Gamble M., Naar A.M., Erdjument-Bromage H., Tempst P., and Freedman L.P. Ligand-dependent transcription activation by nuclear receptors requires the DRIP complex. Nature 398 (1999) 824-828
63. Rao A., Coan A., Welsh J.E., Barclay W.W., Koumenis C., and Cramer S.D. Vitamin D receptor and p21/WAF1 are targets of genistein and 1, 25-dihydroxyvitamin D3 in human prostate cancer cells. Cancer Res. 64 (2004) 2143-2147
64. Shah S., Islam M.N., Dakshanamurthy S., Rizvi I., Rao M., Herrell R., Zinser G., Valrance M., Aranda A., Moras D., Norman A., Welsh J., and Byers S.W. The molecular basis of vitamin D receptor and beta-catenin crossregulation. Mol. Cell 21 (2006) 799-809
65. Simboli-Campbell M., Gagnon A.M., Franks D.J., and Welsh J.E. 1, 25-Dihydroxyvitamin D3 translocates protein kinase Cß to nucleus and enhances plasma membrane association of protein kinase C-alpha in renal epithelial cells. J. Biol. Chem. 269 (1994) 3257-3264
66. Skowronski R.J., Peehl D.M., and Feldman D. Vitamin D and prostate cancer: 1, 25 dihydroxyvitamin D3 receptors and actions in human prostate cancer cell lines. Endocrinology 132 (1993) 1952-1960
67. Solomon C., White J.H., and Kremer R. Mitogen-activated protein kinase inhibits 1, 25-dihydroxyvitamin D3-dependent signal transduction by phosphorylating human retinoid X receptor alpha. J. Clin. Invest. 103 (1999) 1729-1735
68. Sprenger C.C., Peterson A., Lance R., Ware J.L., Drivdahl R.H., and Plymate S.R. Regulation of proliferation of prostate epithelial cells by 1, 25- dihydroxyvitamin D3 is accompanied by an increase in insulin-like growth factor binding protein-3. J. Endocrinol. 170 (2001) 609-618
69. Stoorvogel W., Straus G.J., Geuse H.J., Dorschot V., and Schwartz A.L. Late endosomes derive from early endosomes by maturation. Cell 65 (1991) 417-427
70. Vieth R., McCarten K., and Norwich K.H. Role of 25-hydroxyvitamin D3 dose in determining rat 1, 25-dihydroxyvitamin D3 production. Am. J. Physiol. 258 (1990) E780-E789
71. Wang T.T., Tavera-Mendoza L.E., Laperriere D., Libby E., MacLeod N.B., Nagai Y., Bourdeau V., Konstorum A., Lallemant B., Zhang R., Mader S., and White J.H. Large-scale in silico and microarray-based identification of direct 1, 25-dihydroxyvitamin D3 target genes. Mol. Endocrinol. 19 (2005) 2685-2695
72. White P., and Cooke N. The multifunctional properties and characteristics of vitamin D-binding protein. Trends Endocrinol. Metab. 11 (2000) 320-327
73. Wu W., Zhang X., and Zanello L.P. 1alpha, 25-Dihydroxyvitamin D(3) antiproliferative actions involve vitamin D receptor-mediated activation of MAPK pathways and AP-1/p21(waf1) upregulation in human osteosarcoma. Cancer Lett. 254 (2007) 75-86
74. Zehnder D., Bland R., Williams M.C., McNinch R.W., Howie A.J., Stewart P.M., and Hewison M. Extrarenal expression of 25-hydroxyvitamin d(3)-1 alpha-hydroxylase. J. Clin. Endocrinol. Metab. 86 (2001) 888-894
75. Zhuang S.H., and Burnstein K.L. Antiproliferative effect of 1alpha, 25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Endocrinology 139 (1998) 1197-1207
76. Zhuang S.H., Schwartz G.G., Cameron D., and Burnstein K.L. Vitamin D receptor content and transcriptional activity do not fully predict antiproliferative effects of vitamin D in human prostate cancer cell lines. Mol. Cell Endocrinol. 126 (1997) 83-90